These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience. Dao BD; Ho H; Quintal LN J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300 [TBL] [Abstract][Full Text] [Related]
7. A stable model of chronic bilateral ventricular insufficiency (dilated cardiomyopathy) induced by arteriovenous anastomosis and doxorubicin administration in sheep. Chekanov VS J Thorac Cardiovasc Surg; 1999 Jan; 117(1):198-9. PubMed ID: 9869781 [No Abstract] [Full Text] [Related]
8. Electrophysiological and phenotypic profiles of taxane-induced neuropathy. Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Boyle F; Goldstein D; Park SB Clin Neurophysiol; 2020 Aug; 131(8):1979-1985. PubMed ID: 32291143 [TBL] [Abstract][Full Text] [Related]
9. Two important determinants may play a role in the success of the FinHer Trial. Isik M; Dizdar O; Altundag K J Clin Oncol; 2010 Jul; 28(20):e334; author reply e335-6. PubMed ID: 20124158 [No Abstract] [Full Text] [Related]
10. Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin. Katamadze NA; Lartsuliani KP; Kiknadze MP Georgian Med News; 2009 Jan; (166):43-8. PubMed ID: 19202217 [TBL] [Abstract][Full Text] [Related]
11. [Acute typhlitis associated with taxane-based chemotherapy]. Gagliano E; Tonante A; Taranto F; Mamo M; Sturniolo G; Colonese F; Sturniolo G G Chir; 2010; 31(11-12):514-7. PubMed ID: 21232195 [TBL] [Abstract][Full Text] [Related]
12. [Primary systemic chemotherapy for breast cancer]. Takada M; Toi M Gan To Kagaku Ryoho; 2007 Nov; 34(11):1730-4. PubMed ID: 18030005 [TBL] [Abstract][Full Text] [Related]
13. When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial. De Rossi C; Brunello A; Jirillo G; Jirillo A Immunopharmacol Immunotoxicol; 2009 Mar; 31(1):30-1. PubMed ID: 21054206 [TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicities of breast cancer treatment. Viale PH; Yamamoto DS Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):19-24. PubMed ID: 19856594 [No Abstract] [Full Text] [Related]
15. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802 [TBL] [Abstract][Full Text] [Related]
16. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? van den Berg MP; van Spaendonck-Zwarts KY; van Veldhuisen DJ; Gietema JA; Postma A; van Tintelen JP Eur J Heart Fail; 2010 Dec; 12(12):1297-9. PubMed ID: 20952769 [No Abstract] [Full Text] [Related]
17. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907 [TBL] [Abstract][Full Text] [Related]
18. Re: Lymphopenia associated with adjuvant anthracycline/taxane regimens. Cadoo K; Lowery M; McCaffrey J Clin Breast Cancer; 2009 Nov; 9(4):262. PubMed ID: 19933084 [No Abstract] [Full Text] [Related]
19. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443 [TBL] [Abstract][Full Text] [Related]
20. Improved chemical strategies for the targeted therapy of cancer. Maison W; Frangioni JV Angew Chem Int Ed Engl; 2003 Oct; 42(39):4726-8. PubMed ID: 14562338 [No Abstract] [Full Text] [Related] [Next] [New Search]